The first patient dosed in Australia with INNOGEN-B(02591) in a Phase II clinical trial for the treatment of obesity and overweight with exenatide alpha was completed.
Silver Noble Pharmaceuticals-B (02591) announces that on August 25, 2025, the company has completed the acquisition in Australia...
INNOGEN-B (02591) announces that on August 25, 2025, the company has dosed the first patient in Australia with IISupageglutide-alpha for the treatment of obesity and overweight in a phase II clinical trial. The company anticipates that approximately 200 participants will be enrolled in this clinical trial.
Related Articles
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
